Latest glioblastoma Stories

Johns Hopkins researchers use a type of stem cells from human adipose tissue to chase migrating cancer cells In laboratory studies, Johns Hopkins researchers say they have found that stem cells from a patient's own fat may have the potential to deliver new treatments directly into the brain after the surgical removal of a glioblastoma, the most common and aggressive form of brain tumor. The investigators say so-called mesenchymal stem cells (MSCs) have an unexplained ability to seek out...

BETHESDA, Md., March 7, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that it expects to complete enrollment in its 312-patient Phase III clinical trial for Glioblastoma multiforme (GBM) brain cancer within a period that is faster or more efficient than relevant comparison trials with immune therapies for the same brain cancer. The...

Voices Against Brain Cancer responds to an article which states that scientists have potentially discovered a genetic origin for the deadliest form of brain tumor, glioblastoma. New York, NY (PRWEB) February 16, 2013 On February 16, Voices Against Brain Cancer (VABC) responds to new research that sheds light on the origins of glioblastoma multiforme, the deadliest and most common form of brain cancer. An article from Discover Magazine discusses recent findings that show that...

Voices Against Brain Cancer offers support to Heather Knies, a now cancer free mother who battled two brain tumors. New York, NY (PRWEB) January 19, 2013 On January 19, Voices Against Brain Cancer (VABC) congratulates Heather Knies, who beat two brain tumors and is now cancer free and the mother of a seven-month-old daughter. Knies was diagnosed with two brain tumors at age 24. ABC News states that while this is on the young side, doctors say that people can get brain cancer at any age,...

IRVING, Texas, Nov. 12, 2012 /PRNewswire/ -- Caris Life Sciences(TM), a leading biosciences company focused on enabling personalized healthcare through molecular profiling and blood-based diagnostic services, has added ROS1 and MGMT-Methylation to the company's evidence-based molecular profiling service. The company is one of only a few entities that offer both of these tests commercially. These markers are believed to serve as clinically-important aids in the development of...

Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes. The study also found that drugs that target the protein produced by this genetic aberration can dramatically slow the growth of glioblastomas in mice. The findings were published today in the online edition of the journal Science. "Our findings are doubly important," said study...

In the news release, Novocure(TM) to Present NovoTTF(TM) Therapy Data at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology, issued 29-May-2012 by Novocure over PR Newswire, we are advised by the company that the third paragraph and subsequent bullet have been updated with the correct time and session title. The complete, corrected release follows: Novocure(TM) to Present NovoTTF(TM) Therapy Data at the 2012 Annual Scientific Meeting of the American Society of...

PORTSMOUTH, N.H., May 29, 2012 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that data from pre-clinical and clinical studies evaluating NovoTTF(TM) therapy will be presented and published online as part of the 48th Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, June 1-5, 2012. The data include the trial design of an ongoing Phase III (IDE) clinical trial of tumor-treating fields (TTFields) together...

PORTSMOUTH, N.H., May 14, 2012 /PRNewswire/ -- In its ongoing effort to help patients, their caregivers and health care professionals easily find detailed information about its NovoTTF(TM) therapy for recurrent glioblastoma, Novocure(TM) today unveiled its U.S.-focused NovoTTF(TM) Therapy Website, found at www.novottftherapy.com. Novocure(TM), a commercial stage private oncology company, manufactures the NovoTTF(TM)-100A,( )a wearable device that delivers tumor treating fields...

Study is first to show feasibility and efficacy of a new use for autologous stem cell transplant For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy. Initial results of the ongoing, small clinical trial of three patients with glioblastoma showed that two patients survived longer than predicted if they had not...